Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) EBIT Margin: 2014-2025

Historic EBIT Margin for vTv Therapeutics (VTVT) over the last 10 years, with Sep 2025 value amounting to 213,980.00%.

  • vTv Therapeutics' EBIT Margin was N/A to 213,980.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -2,966.67%, marking a year-over-year change of. This contributed to the annual value of -2,377.58% for FY2024, which is 2693506.00% up from last year.
  • Per vTv Therapeutics' latest filing, its EBIT Margin stood at 213,980.00% for Q3 2025, which was up 843.59% from -28,776.47% recorded in Q4 2024.
  • In the past 5 years, vTv Therapeutics' EBIT Margin registered a high of 400,000.00% during Q2 2023, and its lowest value of -123,433.33% during Q4 2021.
  • In the last 3 years, vTv Therapeutics' EBIT Margin had a median value of 67,242.86% in 2023 and averaged 111,236.67%.
  • In the last 5 years, vTv Therapeutics' EBIT Margin slumped by 12,346,193bps in 2021 and then soared by 44,474,444bps in 2023.
  • vTv Therapeutics' EBIT Margin (Quarterly) stood at -123,433.33% in 2021, then surged by 5,295,556bps to -70,477.78% in 2022, then spiked by 13,772,063bps to 67,242.86% in 2023, then tumbled by 9,601,933bps to -28,776.47% in 2024, then reached 213,980.00% in 2025.
  • Its last three reported values are 213,980.00% in Q3 2025, -28,776.47% for Q4 2024, and -562.70% during Q1 2024.